Psyence Biomedical Ltd.
PBM
$5.21
-$0.445-7.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 105.04% | 88.45% | 71.97% | 24.18% | -0.22% |
| Depreciation & Amortization | 2,050.00% | 3,100.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.46% | 27.57% | -2.49% | -32.07% | -31.11% |
| Operating Income | -75.46% | -27.57% | 2.49% | 32.07% | 31.11% |
| Income Before Tax | 99.35% | 11.19% | -1,204.77% | -1,236.41% | -1,503.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 99.35% | 11.19% | -1,204.77% | -1,236.41% | -1,503.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.35% | 11.19% | -1,204.77% | -1,236.41% | -1,503.64% |
| EBIT | -75.46% | -27.57% | 2.49% | 32.07% | 31.11% |
| EBITDA | -198.84% | -463.62% | -- | -- | -- |
| EPS Basic | 102.24% | 5.92% | -15,501.67% | -- | -- |
| Normalized Basic EPS | -71.39% | -199.74% | -587.46% | -- | -- |
| EPS Diluted | 102.23% | 5.92% | -15,501.83% | -- | -- |
| Normalized Diluted EPS | -71.35% | -199.68% | -587.35% | -- | -- |
| Average Basic Shares Outstanding | 1,057.44% | 889.06% | 383.93% | -- | -- |
| Average Diluted Shares Outstanding | 1,057.59% | 889.29% | 384.38% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |